Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice -January 18, 2024 at 12:01 pm EST
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis in two randomized controlled Phase 3 Clinical Trials FDA Supplemental New Drug Application...
Source: marketscreener.com